About this trial
This study is a nationwide multicenter, single-arm, retrospective study. The study aims to conduct a detailed analysis of operation-related parameters, aesthetic outcomes (e.g., BREAST-Q scores and Harris scores), and safety (e.g., surgical complication rates) in delayed endoscopic direct-to-implant breast reconstruction via the axillary approach.
Eligibility criteria
Qualifiers
Breast cancer patients who underwent delayed endoscopic direct-to-implant breast reconstruction after simple mastectomy at various centers from July 2024 to August 2025, all delayed endoscopic direct-to-implant breast reconstructions were performed ≥ 6 months after the initial mastectomy.
Disqualifiers
Poor skin elasticity;
Re-evaluation (based on clinical, imaging, and pathological findings) indicates local or regional recurrence or uncontrolled distant metastasis;
Patients who have previously undergone radical mastectomy;
Patients who refused to provide postoperative follow-up information.
Trial design
Treatments tested in this trial
- delayed endoscopic direct-to-implant breast reconstruction via axillary approach after simple mastectomy
Treatment groups
Sponsors and collaborators
Du Zhenggui
Lead sponsor
West China Hospital
Sponsor institution
Fujian Cancer Hospital
Collaborator
Suzhou Municipal Hospital
Collaborator
The Second People's Hospital of Yibin
Collaborator
Mianyang Central Hospital
Collaborator
West China Hospital
Collaborator
Fourth People's Hospital of Sichuan Province
Collaborator